The pharmaceutical industry accounts for a substantial chunk of the US economy's research
and development investments, which have resulted in significant medical breakthroughs. At …

Biologics are important treatments for a number of cancers, but they are also significant
drivers of globally escalating healthcare costs. Biosimilars have the potential to offer cost …

Objectives The growing focus on the value of new drugs for patients and society has led to a
more differentiated notion of innovation in the context of pharmaceutical products. The goal …

This chapter describes the market for pharmaceuticals, which exceeded $500 million in
sales in 2010. The industry is also characterized by extensive regulation of almost every …

Importance There is no decision-making framework in the early-adoption stage of novel
surgical technologies, putting the quality of health care and resource allocation of the health …

Increased health care spending has placed pressure on public and private payers to
prioritize spending. Cost-effectiveness (CE) analysis is the main tool used by payers to …

Objective. To estimate patients' elasticity of demand, willingness to pay, and consumer
surplus for five high‐cost specialty medications treating metastatic disease or hematologic …

Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to
inform decisions about access and reimbursement. We study how CE thresholds imposed …

Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of
treatment value in HTA Page 1 HEALTH ECONOMICS Health Econ. 19: 1510 (2010) Published …

Background Contemporary debates about drug pricing feature several widely held
misconceptions, including the relationship between incentives and innovation, the …